Drug Profile
Leucine/metformin/sildenafil - NuSirt Biopharma
Alternative Names: Leu-Met-Sil; Leucine/sildenafil/metformin; Metformin/leucine/sildenafil; Metformin/sildenafil/leucine; NS-0200; Sildenafil/leucine/metformin; Sildenafil/metformin/leucineLatest Information Update: 30 Nov 2022
Price :
$50
*
At a glance
- Originator NuSirt Biopharma
- Class Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; SIRT1 protein stimulants; Sirtuin modulators; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-alcoholic fatty liver disease
- No development reported Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 30 Nov 2022 No development reported - Phase-II for Obesity in USA (PO)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 17 Aug 2018 NuSirt Biopharma completes a phase II trial in Obesity in USA (PO) (NCT03364335)